Kestrel Therapeutics

Health Care · Biotechnology

Overview

Kestrel Therapeutics discovers and develops new molecules to treat intractable cancers using targeted therapy.

Funding and backers

Total raised
$7.5M
4 rounds on record
Latest round
$7.5M
Venture round · Dec 2021 · 4 yr ago
The money's age
Long since its last round
58 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 28, 2025 Took on debt financing $5M · SEC Form D Feb 7, 2025 Took on debt financing $8M · SEC Form D Dec 28, 2021 Raised a round Venture round $7.5M · SEC Form D Mar 1, 2021 Took on debt financing $228k · SEC Form D 2020 Founded
Funding rounds
RoundDateAmountInvestorsSource
Debt Financing Jul 2025 $5M — SEC Form D
Debt Financing Feb 2025 $8M — SEC Form D
Venture round Dec 2021 $7.5M — SEC Form D
Debt Financing Mar 2021 $228k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Kestrel Therapeutics Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Frank HaluskaExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
DCVC
backs DVLP Medicines
RA Capital Management
backs Pyxis Oncology
F-Prime Capital
backs AvenCell
Wellington Management
backs Fore Biotherapeutics
LG Technology Ventures
backs Fore Biotherapeutics
OrbiMed
backs Fore Biotherapeutics
Similar startupsby what they do, their industry and backers
GenomateConvertible Note $2M · 20 mo ago · Founded 2022 · 51-200 employees
Genomate helps physicians find the right targeted therapy for every cancer patient based on the individual molecular profile of their…
Radar Therapeutics
Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Fore BiotherapeuticsSeries D $67.4M · 4 mo ago · 51-200 employees
Leading the future of targeted therapies for the hardest to treat cancers. Wednesday, October 15, 202512:00 pm ET.
TaviraTX11-50 employees
Tavira Therapeutics develops an innovative technology that equips AAV vectors with molecules to accurately target the intended tissues.
Kamal TherapeuticsVenture round $13.8M · 11 mo ago · Founded 2020 · 51-200 employees
Developing intravenous recombinant human decorin to treat dystrophic epidermis bullosa.. Kamal Therapeutics, Inc.
Pyxis OncologyVenture round $172.5M · 5 yr ago · Founded 2018
Charting a course to therapeutics for difficult-to-treat cancers.

Financials

Total raised
$20.7M
Latest round
Debt Financing
Funding rounds
4
Funding rounds
Round Announced Amount
Debt Financing 2025 $5M Details
Debt Financing 2025 $8M Details
Venture - Series Unknown 2021 $7.5M Details
Debt Financing 2021 $228k Details

People

Frank Haluska
Executive Officer, Director
SEC Form D
Denis Patrick
Director
SEC Form D
Omar Khalil
Director
SEC Form D
Andrew Phillips
Director
SEC Form D
Nicholas Saccomano
Director
SEC Form D
Barbara Sosnowski
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
Boston United States
HQ
Watertown United States
HQ
William C. Hahn, MD, PHD
321 Arsenal Street, Suite 301, Watertown, MA 02472
company site